Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-078704
Filing Date
2025-08-14
Accepted
2025-08-14 16:38:18
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9625
  Complete submission text file 0001104659-25-078704.txt   11323
Mailing Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840 203-404-1172
Nantahala Capital Management, LLC (Filed by) CIK: 0001472322 (see all company filings)

EIN.: 201151760 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Subject) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92874 | Film No.: 251220190
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)